Bolt Biotherapeutics, Inc. Total Contract Liability
Bolt Biotherapeutics, Inc. (BOLT) had Total Contract Liability of $3.10 million as of 2023-12-31, per its 10-K filed 2024-03-21.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2024-03-21
- 2023-12-31: Contract with Customer, Liability $3.10M.
- 2023-09-30: Contract with Customer, Liability $3.40M.
- 2023-06-30: Contract with Customer, Liability $4.60M.
- 2023-03-31: Contract with Customer, Liability $4.70M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2023-12-31 | $3.10M 10-K · filed 2024-03-21 |
| 2023-09-30 | $3.40M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.60M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $4.70M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $8.50M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |